ATE170402T1 - Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima - Google Patents

Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima

Info

Publication number
ATE170402T1
ATE170402T1 AT94909627T AT94909627T ATE170402T1 AT E170402 T1 ATE170402 T1 AT E170402T1 AT 94909627 T AT94909627 T AT 94909627T AT 94909627 T AT94909627 T AT 94909627T AT E170402 T1 ATE170402 T1 AT E170402T1
Authority
AT
Austria
Prior art keywords
intimal hyperplasia
pdgf
antibodies
receptor antibody
methods
Prior art date
Application number
AT94909627T
Other languages
English (en)
Inventor
Charles E Hart
Richard D Kenagy
Alexander W Clowes
Original Assignee
Zymogenetics Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc, Univ Washington filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE170402T1 publication Critical patent/ATE170402T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94909627T 1993-02-25 1994-02-17 Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima ATE170402T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2350493A 1993-02-25 1993-02-25

Publications (1)

Publication Number Publication Date
ATE170402T1 true ATE170402T1 (de) 1998-09-15

Family

ID=21815476

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94909627T ATE170402T1 (de) 1993-02-25 1994-02-17 Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima

Country Status (8)

Country Link
EP (1) EP0686044B1 (de)
JP (1) JP2944218B2 (de)
AT (1) ATE170402T1 (de)
CA (1) CA2156825C (de)
DE (1) DE69413009T2 (de)
DK (1) DK0686044T3 (de)
ES (1) ES2122248T3 (de)
WO (1) WO1994019016A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228600B1 (en) 1992-07-20 2001-05-08 The United States Of America As Represented By The Department Of Health And Human Services Immunoassays for the alpha platelet-derived growth factor receptor
US7252929B2 (en) 1989-02-09 2007-08-07 United States Of America, As Represented By The Secretary, Dept Of Health & Human Services Methods for identifying alpha PDGFR agonists and antagonists
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5882644A (en) * 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
AU6497198A (en) * 1997-02-14 1998-09-08 Boehringer Mannheim Gmbh Improved method for the reduction of neointima formation after angioplasty
AU1454199A (en) * 1997-11-07 1999-05-31 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
CA2396628A1 (en) 2000-01-25 2001-08-02 Edwards Lifesciences Corporation Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia
US6990848B2 (en) * 2002-08-05 2006-01-31 Trxoler Electronic Laboratories, Inc. System and method for determining material properties of samples
BRPI0611984A2 (pt) 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ246242A (en) * 1991-12-02 1996-01-26 Cor Therapeutics Inc Inhibiting immunoglobulins acting on beta-platelet derived growth factor (pdgf)

Also Published As

Publication number Publication date
JP2944218B2 (ja) 1999-08-30
DK0686044T3 (da) 2000-10-09
EP0686044B1 (de) 1998-09-02
WO1994019016A1 (en) 1994-09-01
CA2156825C (en) 2003-10-21
EP0686044A1 (de) 1995-12-13
DE69413009D1 (de) 1998-10-08
JPH08507063A (ja) 1996-07-30
ES2122248T3 (es) 1998-12-16
CA2156825A1 (en) 1994-09-01
DE69413009T2 (de) 1999-03-25

Similar Documents

Publication Publication Date Title
DK0801572T3 (da) Sammensætning til inhibering af intimal hyperplasi ved anvendelse af PDGF-antagonister og heparin
DE69632402D1 (en) 4-(2-(n-(-2-carboxamidoindole)aminiethyl)-benzensulfonamide oder sulfonylharnstoffe als pdgf antagoniste
DK0975672T3 (da) Antistoffer til inhibition af blodkoagulation og fremgangsmåder til anvendelse heraf
NZ527076A (en) Graft rejection inhibitors used in combination with immunosuppressants
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
DK0673255T3 (da) Monoklonale antistoffer, som specifikt binder til vaskulært tumorendotel, og anvendelser deraf
DE69323768D1 (de) Pyrrolopyrimidine als crf antagonisten
DE69433406T2 (de) Antikörper gegen cd40
DE68927697T2 (de) Fluor substituierte Benzocycloheptapyridine, Zusammensetzungen und Verfahren zur Verwendung derselben als antihistaminische Verbindungen
ATE170402T1 (de) Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima
DK0831807T3 (da) Anvendelse af Brefeldin A og derivater deraf til fremstilling af lægemidler til behandling af hyperplasia og beslægtede lidelser
DE69434221D1 (de) Bindungs domänen von plasmodium vivax und plasmodium falciparum erythrozyten-bindenden proteinen
ES2216630T3 (es) Metodos de tratar la hipertension dependiente de la sal.
DE69915977D1 (de) Neuartige Heparin bindende Peptide
WO2003010201A3 (en) Blood group antigen fusion polypeptides and methods of use thereof
WO1996040766A3 (en) Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
DE69226531T2 (de) Hemmung von Gefässverengung unter Verwendung von anti-PADGEM Antikörpern.
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
DE69428272T2 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
WO1993025577A3 (en) Active component of parathyroid hypertensive factor
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
ATE147106T1 (de) Anti-oncostatin-m monoklonale antikörper
DK0656906T3 (da) Endothelcellemolekyle, der medierer lymfocytbinding i mennesket

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee